Published: November 2024 | Last updated: May 2026
Gonorrhea used to be the sexually transmitted infection medicine had figured out. A shot of penicillin in the 1950s, a course of pills in the 1980s, a different regimen in the 2000s, and the infection cleared. Today, gonorrhea has burned through almost every antibiotic class ever used against it, and the World Health Organization classifies its resistance profile as a priority public-health threat.
For most readers this is not cause for alarm. It does warrant attention. The way doctors treat gonorrhea changed in 2020 in a way most online guides have not caught up with, and the math on testing has shifted: catching an infection early, before resistant strains can spread further, is now the single highest-impact thing an individual can do. This guide explains what changed, why it changed, and what protects you in practice in 2026.
What “Antibiotic-Resistant Gonorrhea” Actually Means
Antibiotic resistance is biology, not bureaucracy. When you treat a population of bacteria with an antibiotic, the small percentage carrying mutations the drug cannot fully neutralize survive while the rest die off. Those survivors reproduce, and their offspring inherit the same protective trait. Repeat the cycle across millions of people over decades, and you end up with bacterial strains that shrug off the drug entirely.
Neisseria gonorrhoeae, the bacterium that causes gonorrhea, is unusually good at this. It picks up DNA fragments from its environment, including from harmless Neisseria species that live in the human throat, and stitches useful genetic snippets into its own chromosome. The CDC’s drug-resistant Neisseria gonorrhoeae reference describes the bacterium as having developed resistance to nearly every antibiotic class used to treat it. That is not hyperbole; it is the lived history of treatment over the past eight decades.
The practical implication is straightforward. Every new strain that survives current treatment is one step closer to a future where gonorrhea is harder, slower, and more expensive to cure. The drugs that worked for your grandparents do not work today, and the drugs that work today may not work for your children.
Why Resistance Has Outpaced Treatment
Four pressures are running at once. Any one of them would be enough to drive resistance upward; together they explain why every replacement drug since penicillin has had a shorter useful life than the one before it.
Heavy antibiotic use across the population. The more an antibiotic circulates, the more selection pressure it places on bacteria. Gonorrhea has been treated empirically (before lab confirmation) for decades, often as part of broad combination regimens for suspected STIs. Each course is an evolution event.
The bacterium’s plasticity. N. gonorrhoeae swaps DNA with neighboring bacteria. Harmless Neisseria species living in the human throat act as a quiet reservoir for resistance genes that gonorrhea then exports back into genital infections via oral sex.
A thin antibiotic pipeline. Developing a new antibiotic takes roughly a decade and costs hundreds of millions of dollars. Because antibiotics are short courses with low profit margins, most large pharmaceutical companies left the space years ago. The drugs we have now are largely the drugs we will have for the foreseeable future, with the rare exceptions discussed later in this article.
Global travel and trade. A resistant strain that emerged in one city once took years to spread. Today, a single international flight can carry it to a new continent in hours, and the strain establishes itself wherever local treatment patterns let it survive. Surveillance from the World Health Organization has documented multidrug-resistant strains across multiple regions globally (see the WHO STI fact sheet).
| Antibiotic class | Period of first-line use (U.S.) | When resistance became widespread |
|---|---|---|
| Sulfonamides | 1930s–1940s | Late 1940s |
| Penicillin | 1940s–1980s | 1970s–1980s |
| Tetracyclines | 1970s–1980s | 1980s |
| Fluoroquinolones (ciprofloxacin) | 1990s–2007 | Mid-2000s |
| Ceftriaxone + azithromycin (dual therapy) | 2010–2020 | Late 2010s azithromycin resistance |
| Ceftriaxone alone (current) | 2020 to present | Sporadic XDR cases reported globally |
What Doctors Use to Treat Gonorrhea Right Now
This is the single biggest practical change since most online guides were written. In December 2020 the CDC updated its sexually transmitted infections treatment guidelines and moved gonorrhea from dual therapy (ceftriaxone plus azithromycin) to a single intramuscular dose of ceftriaxone at 500 milligrams. The 2021 guideline document codified the update, and it remains current guidance.
Two factors drove the change: rising azithromycin resistance in U.S. surveillance samples, and clinical evidence that the higher-dose ceftriaxone alone reliably cleared infections. Patients weighing 150 kilograms or more receive a 1 gram dose. Pharyngeal (throat) infections, which are notoriously harder for antibiotics to penetrate, receive the same regimen but with a follow-up test of cure 7 to 14 days later to confirm clearance.
Any patient who tests positive for gonorrhea is still treated presumptively for chlamydia at the same visit (typically with doxycycline) unless chlamydia has been actively ruled out. Co-infection rates run high enough that the CDC considers single-pathogen treatment a missed opportunity.
For the up-to-date specifics, which change as resistance patterns shift, the CDC’s gonorrhea treatment guidance for adolescents and adults is the authoritative reference for clinicians and the source most labs and sexual-health services work from.
If your provider prescribes treatment for gonorrhea, finish the entire course exactly as directed even when symptoms clear within a day or two. Partial dosing is a major driver of resistance: the bacteria that survive the first round carry the mutations that let them tolerate the drug, and those survivors are the ones that go on to infect partners.
What Happens When Gonorrhea Goes Untreated
Untreated gonorrhea does not sit quietly. The bacterium continues replicating and migrating, and the longer it persists the more damage it can do. The consequences differ by anatomy and by infection site, but the general pattern holds: an infection that was easy to cure when caught early becomes harder to treat and more likely to leave lasting effects the longer it remains.
In people with female reproductive anatomy, gonorrhea can ascend from the cervix into the uterus and fallopian tubes, causing pelvic inflammatory disease (PID). PID scars the reproductive tract and is a leading cause of tubal-factor infertility and ectopic pregnancy. The CDC estimates that a meaningful share of infertility cases trace back to untreated chlamydia or gonorrhea infections years earlier.
In people with male reproductive anatomy, untreated infection can spread to the epididymis (the tube that stores sperm), causing painful swelling and, more rarely, scarring that affects fertility. Disseminated gonococcal infection, where the bacterium enters the bloodstream, is uncommon but serious; it can present as skin rash, joint pain, and fever.
During pregnancy, gonorrhea raises the risk of preterm delivery, premature rupture of membranes, and transmission to the newborn at delivery. Newborn transmission can cause a severe eye infection called ophthalmia neonatorum. Routine prenatal screening catches most cases in time to treat before birth.
For everyone, an active gonorrhea infection inflames mucosal tissue and meaningfully increases the risk of acquiring HIV during exposure. The risk amplification is strongest when active inflammation or mucosal disruption is present, conditions that gonorrhea itself can produce in the genital tract. Treating gonorrhea is, indirectly, HIV prevention.
Some complications of untreated gonorrhea need same-day medical attention rather than another round of at-home testing. See a clinician promptly if you notice severe pelvic or lower-abdominal pain, fever with chills, joint swelling or rash, painful testicular swelling, vision changes in a newborn, or any heavy unexplained vaginal bleeding. These can signal pelvic inflammatory disease, disseminated infection, epididymitis, or ophthalmia neonatorum, all of which are treatable but only with antibiotics a clinician can prescribe.
Why Early Detection Matters More Than Ever
If your testing habit is to wait for symptoms before getting checked, that approach was reasonable a generation ago. It is no longer reasonable. Two facts have shifted the calculation.
First, most early gonorrhea infections are asymptomatic. Per public-health surveillance, many urogenital gonorrhea infections in women produce no clear symptoms, while male urogenital infections more often produce symptoms; pharyngeal and rectal infections are silent more often still. By the time visible symptoms appear, the bacterium has had weeks of unsupervised access to the body and to sexual partners.
Second, the time between a resistant strain entering circulation and that strain becoming common in your community has been shrinking. Catching an infection in week two instead of month three is the difference between contributing to onward transmission and contributing to outbreak containment. Early detection also protects you personally: treating an infection that has not yet spread to the upper reproductive tract is faster, cheaper, and less likely to cause lasting damage.
The CDC currently recommends annual gonorrhea screening for all sexually active women under age 25 and for older women with risk factors, and at least annual screening for men who have sex with men, with more frequent testing (every 3 to 6 months) for those with multiple or new partners. For everyone else, screening is recommended at any change of partner and at any new exposure of concern (see the CDC STI screening recommendations).
This article is published by stdrapidtestkits.com, which sells the at-home rapid test linked below. We mention it here because it directly serves the early-detection gap discussed above; we recommend kits based on fit-for-purpose for the reader’s concern, not commercial benefit.
How At-Home Testing Fits Into a Resistance Era
An at-home swab test for gonorrhea is a rapid lateral-flow immunoassay, the same chemistry family as a home pregnancy test or a COVID rapid test. You collect a sample yourself (a self-administered swab from the genital site), apply it to a test cassette with the supplied buffer, and read the result in about 15 minutes from the appearance or absence of a colored line.
Three points are worth understanding about how this slots into a resistance-era testing strategy:
- The technology is not equivalent to a lab NAAT. Laboratory nucleic acid amplification tests detect tiny amounts of bacterial DNA and are the analytical gold standard the CDC recommends for diagnosis. A home lateral-flow strip detects bacterial antigens at the levels typical of an established infection. Its strength is speed, privacy, and accessibility, not the maximum analytical sensitivity in very early or very mild cases.
- A positive result requires confirmation and a prescription. Gonorrhea cannot be treated at home. A positive rapid test is the trigger to contact a clinician (in person, by telehealth, or through a sexual-health service) who can prescribe the 500 mg ceftriaxone injection plus the presumptive chlamydia coverage.
- A negative result during the window period does not rule out infection. The first few days after exposure may produce too little bacterial antigen for a rapid test to detect. If the exposure was very recent and your concern is real, retest around day 14, or order a lab NAAT through a sexual-health clinic for higher analytical sensitivity.
Used with those caveats in mind, at-home testing turns “I think I should probably get tested at some point” into “I am testing today.” That compression of time is precisely what slows community spread of resistant strains.
Prevention Strategies That Still Work in 2026
Resistance has changed the consequences of acquiring gonorrhea, but it has not changed how the infection transmits. The prevention playbook is largely the same as it has always been, and every tool on it still works.
Condoms used consistently and correctly. Latex or polyurethane condoms reduce gonorrhea transmission risk substantially across vaginal, anal, and oral sex. The “consistently” part matters as much as the “correctly” part; occasional use offers occasional protection.
Limiting concurrent partners. The math of STI transmission is heavily influenced by how many sexual contacts are circulating in a network at the same time. Fewer concurrent partners shrinks the network in which an infection can spread.
Mutual testing before condomless sex. Testing each partner once at the start of a new sexual relationship, before condom use stops, catches most existing infections before exposure happens. It is a short, awkward conversation that prevents a long, expensive treatment regimen.
Doxy-PEP for higher-risk populations. A regimen of doxycycline 200 mg taken within 72 hours after condomless sex has been shown to reduce bacterial STI acquisition, including gonorrhea, in men who have sex with men and in transgender women. The CDC issued formal doxy-PEP guidance in 2024. It is not appropriate for everyone, and clinicians monitor for its own resistance concerns, but it is a meaningful new tool for higher-risk groups.
Routine screening. Same point as the previous section, restated because it is the single highest-leverage intervention available to an individual: routine testing finds asymptomatic infections that prevention conversations miss.
Treatments in the Pipeline
Two drugs are worth knowing about because they represent the first genuinely new mechanisms of action against gonorrhea in roughly two decades.
Zoliflodacin is a topoisomerase inhibitor with a binding pocket distinct from fluoroquinolones, which means fluoroquinolone-resistant strains do not have pre-existing resistance to it. The Global Antibiotic Research and Development Partnership (GARDP) completed a phase 3 trial in 2023 showing non-inferiority to the existing ceftriaxone-plus-azithromycin standard for uncomplicated urogenital gonorrhea. Regulatory submissions are pending in multiple jurisdictions.
Gepotidacin is a bacterial DNA gyrase and topoisomerase IV inhibitor that received FDA approval for uncomplicated urinary tract infection in 2025 (marketed as Blujepa) and is in advanced trials for gonorrhea. Its dual mechanism makes single-mutation resistance harder to develop than for drugs that bind a single target.
Neither drug is in widespread clinical use for gonorrhea yet. Both could be available as second-line options in the late 2020s if regulatory paths hold. Their existence does not mean current resistance pressure is solved; it means the next decade has at least one fallback if ceftriaxone resistance becomes common enough to compromise first-line treatment.
Gonorrhea has developed resistance to nearly all the antibiotics used for its treatment.
Your Role in Keeping Antibiotics Working
The collective decisions of millions of individuals produced antibiotic resistance, and they are also what can slow it. Four habits matter more than the rest.
Take any prescribed antibiotic course to completion, even when symptoms clear early. The remaining doses are killing the bacteria that survived the first round, and those survivors are the ones most likely to carry resistance mutations.
Do not pressure clinicians for antibiotics for conditions where they are not indicated (most sore throats, most coughs, most sinus infections in their first week). Every unnecessary course adds to background selection pressure across the whole bacterial population.
Test routinely for sexually transmitted infections, especially before stopping condom use with a new partner. Asymptomatic infections caught early require less treatment and contribute less to onward transmission.
Tell partners. Partner notification feels uncomfortable, but it is the single biggest lever an individual has on community-level spread. Most sexual-health services offer anonymous partner-notification options if direct conversation is not workable. Because chlamydia and gonorrhea co-occur often enough that CDC guidance treats them together, a single test that covers both is the practical way to follow through on a notification.
FAQs
- Is gonorrhea still curable in 2026?
- Yes. The CDC’s current first-line treatment is a single 500 mg intramuscular dose of ceftriaxone, with a 1 gram dose for patients weighing 150 kg or more. The large majority of cases clear fully with this regimen. The concern is not that gonorrhea is incurable today; it is that the trajectory of resistance means current treatment may not be reliable indefinitely.
- What is “super gonorrhea”?
- “Super gonorrhea” is a media term for extensively drug-resistant (XDR) strains that fail to respond to multiple antibiotic classes, including the current first-line drug. A small number of XDR cases have been reported in the United Kingdom, Australia, Japan, and other countries. These cases have generally been treatable with extended or off-label regimens, but each one is a warning sign that resistance is advancing.
- How soon after exposure can I test for gonorrhea?
- Lab NAAT testing can detect gonorrhea DNA as early as day 1 after exposure and is most reliable from about day 7 onward. Rapid lateral-flow at-home swab tests are typically reliable from around day 5 to day 14. If your exposure was very recent and the first result is negative, repeat the test around day 14 to confirm.
- Can I treat gonorrhea at home?
- No. There is no over-the-counter or at-home medication that cures gonorrhea. You can diagnose it at home with a rapid test, but a positive result requires a clinician’s prescription for the recommended antibiotic injection plus presumptive chlamydia coverage. Telehealth services handle this process without an in-person visit in many regions.
- How often should I be tested?
- If you’re a sexually active woman under 25: once a year at minimum. Men who have sex with men: at least once a year, and every three to six months if you have multiple or new partners. For everyone else, test at any new partner change or any exposure you’re worried about. Pregnant patients are screened as part of routine prenatal care.
- Does antibiotic resistance reverse if a drug is no longer used?
- Resistance can decline modestly when selection pressure drops, but it rarely reverses fully. Once a resistance gene is established in a bacterial population, it tends to persist. The realistic goal is slowing the spread of resistant strains, not eliminating them. That is why prevention and early detection carry as much weight as new-drug development.
- Are at-home rapid tests as accurate as lab tests?
- For established symptomatic infections, at-home rapid lateral-flow tests perform well. They are not as analytically sensitive as laboratory nucleic acid amplification tests (NAATs), which detect bacterial DNA at very low concentrations. The at-home kit’s role is screening, speed, and privacy. The lab NAAT’s role is confirmation and detection of very early or very low-bacterial-load cases. The two are complementary, not equivalent.
- What should I do if I test positive but have no symptoms?
- Treat it. Asymptomatic gonorrhea can still be transmitted to partners, can still progress to pelvic inflammatory disease, and still contributes to community spread of resistant strains. Contact a clinician for the 500 mg ceftriaxone injection (plus presumptive chlamydia treatment) and notify recent sexual partners so they can test as well.
- U.S. Centers for Disease Control and Prevention. Drug-Resistant Neisseria gonorrhoeae: clinical and public-health reference page covering resistance history, surveillance, and current treatment.
- U.S. Centers for Disease Control and Prevention. STI Treatment Guidelines, Gonococcal Infections Among Adolescents and Adults: source page for the recommended 500 mg ceftriaxone intramuscular regimen and the weight-based 1 gram alternative.
- U.S. Centers for Disease Control and Prevention. STI Screening Recommendations: source page for screening cadence for women under 25, pregnant patients, and men who have sex with men.
- World Health Organization. Sexually transmitted infections fact sheet: global incidence, transmission, antimicrobial-resistance status, and treatment outlook for gonorrhea.
- U.S. Centers for Disease Control and Prevention. STI Statistics: most recent national surveillance data for reportable STIs including chlamydia, gonorrhea, and syphilis.
- U.K. National Health Service. Gonorrhoea overview: symptoms, complications, transmission, and treatment in the U.K. context for cross-checking dosing and screening guidance.
